DYADIC INTERNATIONAL INC DYAI
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
1/9
Piotroski F — financial health
-31.25
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $3.1M | -$7.4M | — | — | $1.2M |
| 2024 | $3.5M | -$5.8M | — | — | $2.5M |
| 2023 | $2.9M | -$6.8M | — | — | $5.9M |
| 2022 | $2.9M | -$9.7M | — | — | $11.1M |
| 2021 | $2.4M | -$13.1M | — | — | $18.4M |
| 2020 | $1.6M | -$9.3M | — | — | $28.4M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| TCHELET RONEN | VP of Research and Bus. Dvlpmt | 2026-01-02 | Grant | 18,064 | — |
| Rawson Ping Wang | Chief Financial Officer | 2026-01-02 | Grant | 29,158 | — |
| Lucy Patrick K. | director | 2026-01-02 | Option exercise | 21,552 | — |
| Kaye Jack | director | 2026-01-02 | Option exercise | 21,552 | — |
| HERBST SETH | director | 2026-01-02 | Option exercise | 21,552 | — |
| Hazelton Joseph P | President & COO | 2026-01-02 | Grant | 36,418 | — |
| EMALFARB MARK A | CEO | 2026-01-02 | Grant | 102,609 | — |
| Hazelton Joseph P | President and COO | 2025-08-01 | Buy | 26,000 | $0.95 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -31.25 (distress)
- Working capital / assets 0.624
- Retained earnings / assets -9.396
- EBIT / assets -0.723
- Equity / liabilities 0.141
Source: SEC EDGAR filings · CIK 0001213809 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.